Open session of the standing technical committee of the EUFMD- 2004

Figure 4 Protection rates (%) for cattle in (a) Sivas-Ulas; (b) Ankara-Bala; (c) Urfa-Ceylanpinar; (d) Aksaray and (e) Samsun-Gelemen.

(a) n=30

(b) n=30

100

100 90 80 70 60 50 40 30 20 10 0

80 60

86.66

40

O 90

A 70 Asia-1

20 0

86.66

A

28. day PV

(c) n=100

97

O

Asia-1

28. day PV

100 90 80 70 60 50 40 30 20 10 0

100

93

(d) n=41

98

100 90 80 70 60 50 40 30 20 10 0

O

93

A Asia-1

97.56

100 90.24

O A Asia-1

28. day PV

(e) n=33 100 90 80 70 60 50 40 30 20 10 0

100

90 90

O A Asia-1

28. day PV

126

Turn static files into dynamic content formats.

Create a flipbook

Articles inside

Appendix 20 EMEA paper extract - Recommendations for tests for induction of antibodies to NSP antigens by FMD vaccines

4min

pages 144-145

Appendix 19

18min

pages 136-143

Appendix 14

4min

page 112

Appendix 13

10min

pages 107-111

Appendix 5

2min

page 64

Appendix 12

9min

pages 104-106

Appendix 3

9min

pages 47-49

Appendix 4

26min

pages 50-63

Appendix 8

12min

pages 77-80

Appendix 2

8min

pages 43-46

Open Session

6min

pages 39-42

Closed Session

2min

pages 37-38

Item 11 – Persistent and subclinical infections – diagnostic and surveillance issues

3min

page 33

Item 15 – Managing the decision-making process in control of FMD and in the priority setting of research and development

3min

page 36

Item 14 – Regulatory compliance

2min

page 35

Item 10 – International issues

3min

page 32

Item 9 – Novel vaccines

3min

page 31

Item 7 – Optimisation of conventional vaccines

3min

page 29

Item 4 – Managing diagnostic demands

3min

page 27

Item 8 – Regulatory issues affecting FMD vacine selection and use

3min

page 30

Item 3 – Transmission and its control

3min

page 26

3.4.2 Post-vaccination serosurveillance (PVS) for presence of FMD infected animals

3min

page 16

Item 1 – Recent findings in molecular epidemiology of FMDV

3min

page 24

Item 2 – Surveillance: for what purpose and how much is enough?

3min

page 25

4.2 Collection of sera/specimens for validation of DIVA tests for detection of animals received from SAT virus infection

3min

page 20

Open session of the standing technical committee of the EUFMD- 2004

Articles inside

Appendix 82

Appendix 77

Appendix 78

Appendix 79

Appendix 81

Appendix 80

Appendix 76

Appendix 75

Appendix 64

Appendix 72

Appendix 73

Appendix 65

Appendix 67

Appendix 63

Appendix 62

Appendix 54

Appendix 61

Appendix 55

Appendix 59

Appendix 60

Appendix 56

Appendix 42

Appendix 52

Appendix 50

Appendix 46

Appendix 37

Appendix 38

Appendix 41

Appendix 40

Appendix 36

Appendix 35

Appendix 34

Appendix 28

Appendix 31

Appendix 29

Appendix 33

Appendix 27

Appendix 26

Appendix 25

Appendix 23

Appendix 22

Appendix 15

Appendix 16

Appendix 20 EMEA paper extract - Recommendations for tests for induction of antibodies to NSP antigens by FMD vaccines

Appendix 19

Appendix 14

Appendix 13

Appendix 5

Appendix 12

Appendix 3

Appendix 4

Appendix 8

Appendix 2

Open Session

Closed Session

Item 11 – Persistent and subclinical infections – diagnostic and surveillance issues

Item 15 – Managing the decision-making process in control of FMD and in the priority setting of research and development

Item 14 – Regulatory compliance

Item 10 – International issues

Item 9 – Novel vaccines

Item 7 – Optimisation of conventional vaccines

Item 4 – Managing diagnostic demands

Item 8 – Regulatory issues affecting FMD vacine selection and use

Item 3 – Transmission and its control

3.4.2 Post-vaccination serosurveillance (PVS) for presence of FMD infected animals

Item 1 – Recent findings in molecular epidemiology of FMDV

Item 2 – Surveillance: for what purpose and how much is enough?

4.2 Collection of sera/specimens for validation of DIVA tests for detection of animals received from SAT virus infection